Christina M. Lalama

HIV-1 DNA Decay Dynamics in Blood During More Than a Decade of Suppressive Antiretroviral Therapy

Guillaume Besson, Christina M. Lalama, Ronald J. Bosch et al. · Clinical Infectious Diseases · 2014 · 224 citations · Full text

Life Sciences, Microbiology, Molecular Biology +16

Pre‐existing Minority Drug‐Resistant HIV‐1 Variants, Adherence, and Risk of Antiretroviral Treatment Failure

Roger Paredes, Christina M. Lalama, Heather J. Ribaudo et al. · The Journal of Infectious Diseases · 2010 · 204 citations · Full text

Life Sciences, Pharmacology, Epidemiologic Methods +15

Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation

Rajesh T. Gandhi, Deborah K. McMahon, Ronald J. Bosch et al. · PLoS Pathogens · 2017 · 185 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +13

Preexisting Resistance to Nonnucleoside Reverse‐Transcriptase Inhibitors Predicts Virologic Failure of an Efavirenz‐Based Regimen in Treatment‐Naive HIV‐1–Infected Subjects

Daniel R. Kuritzkes, Christina M. Lalama, Heather J. Ribaudo et al. · The Journal of Infectious Diseases · 2008 · 167 citations · Full text

Life Sciences, Infectious Diseases, Pharmacology +17

Multiple-Dose Escalation Study of the Safety, Pharmacokinetics, and Biologic Activity of Oral AMD070, a Selective CXCR4 Receptor Inhibitor, in Human Subjects

Nimalie D. Stone, Shelia B. Dunaway, Charles Flexner et al. · Antimicrobial Agents and Chemotherapy · 2007 · 124 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +13